Building Robust Manufacturing & Quality Systems to Enable the Commercialization of TIL Therapies

• Establishing CMC quality systems that support consistent TIL manufacturing from early development through commercialization
• Exploring lessons learned from scaling autologous cell therapies from research to industrial manufacturing while maintaining product quality and regulatory compliance
• Navigating global regulatory expectations and integrating manufacturing, quality, and clinical development strategies to accelerate TIL therapy approval and commercialization

Speakers:

Zhang Changfeng

Chief Exectuitive Officer

Hongzhou Huasai Biomedicine